Literature DB >> 21175561

Role of apoptosis and melanocytorrhagy: a comparative study of melanocyte adhesion in stable and unstable vitiligo.

R Kumar1, D Parsad, A J Kanwar.   

Abstract

BACKGROUND: Apoptosis and melanocytorrhagy have been proposed as mechanisms of melanocyte disappearance although there are few controlled studies.
OBJECTIVES: We undertook this project to study melanocyte morphology and adhesion defects in patients with stable and unstable disease in controls.
METHODS: In this comparative study we included seven patients with stable disease and seven patients with unstable vitiligo. We cultured perilesional skin melanocytes from these patients with stable and unstable vitiligo and studied for morphological changes, adhesion to collagen type IV and caspase 3 expression. Melanocytes were also treated with okadaic acid and annexin V expression was then checked and compared between controls and patients with stable and unstable vitiligo.
RESULTS: Perilesional skin melanocytes from patients with unstable vitiligo revealed some significant morphological changes. Melanocytes from unstable vitiligo showed significantly low adhesion to collagen type IV compared with control and stable vitiligo melanocytes. Our results showed that caspase 3 and annexin V staining was significantly greater in melanocytes cultured from unstable vitiligo compared with the control.
CONCLUSIONS: In this study we demonstrated that melanocytes in the patients with unstable vitiligo were in their detachment phase, which ultimately leads to apoptosis of these cells, whereas melanocytes cultured from controls and from patients with stable vitiligo were morphologically normal without any adhesion defects. These morphological and adhesion findings support the theory of melanocytorrhagy as the primary defect underlying melanocyte loss in unstable vitiligo.
© 2010 The Authors. BJD © 2010 British Association of Dermatologists 2010.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21175561     DOI: 10.1111/j.1365-2133.2010.10039.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  7 in total

Review 1.  Gut-Microbiota-Brain Axis and Its Effect on Neuropsychiatric Disorders With Suspected Immune Dysregulation.

Authors:  Anastasia I Petra; Smaro Panagiotidou; Erifili Hatziagelaki; Julia M Stewart; Pio Conti; Theoharis C Theoharides
Journal:  Clin Ther       Date:  2015-05-01       Impact factor: 3.393

Review 2.  Stability in Vitiligo: Is there a Perfect Way to Predict it?

Authors:  Kanika Sahni; Davinder Parsad
Journal:  J Cutan Aesthet Surg       Date:  2013-04

3.  Protective effect of madecassoside on H2O2-induced oxidative stress and autophagy activation in human melanocytes.

Authors:  Yuting Ling; Qingli Gong; Xixi Xiong; Li Sun; Wene Zhao; Wenyuan Zhu; Yan Lu
Journal:  Oncotarget       Date:  2017-05-07

4.  Evaluation of skin expression profiles of patients with vitiligo treated with narrow-band UVB therapy by targeted RNA-seq.

Authors:  Jorge Ocampo-Candiani; Mauricio Salinas-Santander; Victor Trevino; Rocio Ortiz-López; Jorge Ocampo-Garza; Celia Nohemi Sanchez-Dominguez
Journal:  An Bras Dermatol       Date:  2018 Nov/Dec       Impact factor: 1.896

5.  Dysfunction of ATG7-dependent autophagy dysregulates the antioxidant response and contributes to oxidative stress-induced biological impairments in human epidermal melanocytes.

Authors:  Zhuhui Qiao; Zhongyi Xu; Qing Xiao; Yiwen Yang; Jiayi Ying; Leihong Xiang; Chengfeng Zhang
Journal:  Cell Death Discov       Date:  2020-05-01

Review 6.  Mechanisms of melanocyte death in vitiligo.

Authors:  Jianru Chen; Shuli Li; Chunying Li
Journal:  Med Res Rev       Date:  2020-11-17       Impact factor: 12.944

7.  Methylcobalamin Protects Melanocytes from H2O2-Induced Oxidative Stress by Activating the Nrf2/HO-1 Pathway.

Authors:  Ran An; Dong Li; Yingying Dong; Qiuyun She; Ting Zhou; Xiaoqi Nie; Ronghua Pan; Yunhua Deng
Journal:  Drug Des Devel Ther       Date:  2021-11-30       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.